Evidence map›Paper›PMID 33631276›Full record

ArticleJournal of ethnopharmacology2021

Evaluating the Traditional Chinese Medicine (TCM) Officially Recommended in China for COVID-19 Using Ontology-Based Side-Effect Prediction Framework (OSPF) and Deep Learning.

Zeheng Wang, Liang Li, Miao Song, Jing Yan, Junjie Shi, Yuanzhe Yao

Open access · greenAbstract read
In one paragraph

Article in Journal of ethnopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Evolution from Medical Imaging to Visualized Medicine.Advances in experimental medicine and biology · 2023
    Article
  15. Machine Learning Applications in Drug Repurposing.Interdisciplinary sciences, computational life sciences · 2022
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Zeheng WangSchool of Information and Software Engineering, University of Electronic Science and Technology of China, Chengdu, 610054, People's Republic of China; School of Electrical Engineering and Telecommunications, The University of New South Wales, Sydney, New South Wales, 2052, Australia. Electronic address: zenwang@outlook.com.
Liang LiSchool of Information and Software Engineering, University of Electronic Science and Technology of China, Chengdu, 610054, People's Republic of China. Electronic address: 201821140204@std.uestc.edu.cn.
Miao SongDepartment of Psychiatric Rehabilitation, Mental Health Center of Shaanxi Province, Xi'an, 710061, People's Republic of China. Electronic address: songmiaodocter@163.com.
Jing YanThe First Clinical Medical College, Zhejiang Chinese Medicine University, Hangzhou, 310006, People's Republic of China. Electronic address: jingyan@zcmu.edu.cn.
Junjie ShiSchool of Materials Science and Engineering, The University of New South Wales, Sydney, New South Wales, 2052, Australia. Electronic address: junjie.shi2@unsw.edu.au.
Yuanzhe YaoSchool of Information and Software Engineering, University of Electronic Science and Technology of China, Chengdu, 610054, People's Republic of China. Electronic address: yyz@uestc.edu.cn.
University of Electronic Science and Technology of China · CNUNSW Sydney · AUZhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ethnopharmacological relevanceThe novel coronavirus disease (COVID-19) outbreak in Wuhan has imposed a huge influence in terms of public health and economy on society. However, no effective drugs or vaccines have been developed so far. Traditional Chinese Medicine (TCM) has been considered as a promising supplementary treatment of this disease due to its clinically proven performance in many severe diseases, like severe acute respiratory syndrome (SARS). Meanwhile, many reports suggest that the side-effects (SE) of TCM prescriptions cannot be ignored in treating COVID-19 as it often leads to dramatic degradation of the patients' physical condition. Systematic evaluation of TCM regarding its latent SE becomes a burning issue.

aimIn this study, we used an ontology-based side-effect prediction framework (OSPF) developed from our previous work and Artificial Neural Network (ANN)-based deep learning, to evaluate the TCM prescriptions officially recommended by China for the treatment of COVID-19. MATERIALS AND

methodsThe OSPF developed from our previous work was implemented in this study, where an ontology-based model separated all ingredients in a TCM prescription into two categories: hot and cold. A database was created by converting each TCM prescription into a vector which contained ingredient dosages, corresponding hot/cold attribution and safe/unsafe labels. This allowed for training of the ANN model. A safety indicator (SI), as a complement to SE possibility, was then assigned to each TCM prescription. According to the proposed SI, from high to low, the recommended prescription list could be optimized. Furthermore, in interest of expanding the potential treatment options, SIs of other well-known TCM prescriptions, which are not included in the recommended list but are used traditionally to cure flu-like diseases, are also evaluated via this method.

resultsBased on SI, QFPD-T, HSBD-F, PMSP, GCT-CJ, SF-ZSY, and HSYF-F were the safest treatments in the recommended list, with SI scores over 0.8. PESP, QYLX-F, JHQG-KL, SFJD-JN, SHL-KFY, PESP1, XBJ-ZSY, HSZF-F, PSSP2, FFTS-W, and NHSQ-W were the prescriptions most likely to be unsafe, with SI scores below 0.1. In the additional lists of other TCM prescriptions, the indicators of XC-T, SQRS-S, CC-J, and XFBD-F were all above 0.8, while QF-Y, XZXS-S, BJ-S, KBD-CJ, and QWJD-T's indicators were all below 0.1.

conclusionsIn total, there were 10 TCM prescriptions with indicators over 0.8, suggesting that they could be considered in treating COVID-19, if suitable. We believe this work could provide reasonable suggestions for choosing proper TCM prescriptions as a supplementary treatment for COVID-19. Furthermore, this work introduces a novel and informative method which could help create recommendation list of TCM prescriptions for the treatment of other diseases.

Indexed as

COVID-19 Drug TreatmentChinaDatabases, FactualDeep LearningDrug LabelingDrugs, Chinese HerbalHumansMedicine, Chinese TraditionalNeural Networks, ComputerReference StandardsDrugs, Chinese HerbalArtificial intelligenceCovid-19Deep learningNovel corona virusSide effectTraditional Chinese medicine

Identifiers

PMID33631276
PMCPMC7899032
OpenAlexW3130491026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.